Evaluation of patient perspective of point of care testing and medication: Dispensing by community pharmacists for Streptococcus pyogenes and influenza

Tigges, Courtney; Doucette, William R.; Veach, Stevie; McDonough, Randy P.; Kent, Kelly; Wolff, Kaley; Witry, Matthew J.

doi:10.1016/j.japh.2022.10.006

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A survey conducted in Iowa of those having just received their COVID‐19 vaccine at a pharmacy, who were mostly over 50 years of age, found that pharmacies were not the preferred site for influenza or streptococcal pharyngitis testing. But, most participants noted a willingness to use the pharmacy services 41 . Most surveyed also noted that they would pay an amount equal to or greater than their office copay, and 62% said they would pay more than $25 41 .…”

Section: Economic and Humanistic Outcomesmentioning

confidence: 99%

“…But, most participants noted a willingness to use the pharmacy services 41 . Most surveyed also noted that they would pay an amount equal to or greater than their office copay, and 62% said they would pay more than $25 41 . A qualitative survey of 11 patients in Tennessee and Kentucky who had utilized a pharmacy strep and/or flu test and treatment program identified patients' appreciation of appointment scheduling ease and an efficient process 42 …”

Section: Economic and Humanistic Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Community pharmacist‐provided test and treat programs for acute infectious conditions

Koski

Klepser

Koski

et al. 2023

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Community pharmacists' roles have expanded in recent years to include offering test and treat programs where they perform testing on Clinical Laboratory Improvement Amendment (CLIA)‐waived point‐of‐care testing (POCT) devices to diagnose specific acute infectious conditions, such as influenza and group A streptococcus (GAS) pharyngitis, and then potentially prescribe and dispense appropriate antimicrobials. Availability of these services in pharmacies has several benefits, including increased access to care, decreased overutilization of other health care services, and decreased antimicrobial resistance. States have different requirements for collaborative practice agreements and reimbursement for these clinical services in community pharmacies. Several studies have looked at outcomes related to community pharmacies implementing test and treat programs for influenza and/or GAS. Other studies looked at outcomes related to implementing testing for SARS‐CoV‐2 and referring for treatment. Most studies described successful implementation and barriers to integration of these programs into pharmacy workflow. Some studies showed that patients want these services to be offered in community pharmacies and are willing to pay for the services. Data show that these services are cost effective compared to physician provider‐based treatment. Newer CLIA‐waived POCT technology may increase implementation of these services, but studies are needed to evaluate their utility in community pharmacies. Pharmacy schools should implement widespread training on these devices, and research should continue in this area to test the use of newer technology (i.e., multiplexed devices) and their economic impact.

show abstract

Section: Economic and Humanistic Outcomesmentioning

confidence: 99%